ROCKVILLE, Md., Feb. 25, 2025 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced it will participate in the following investor conferences:
TD Cowen's 45th Annual Health Care Conference
Fireside Chat: Wednesday, March 5 at 1:10pm ET
Location: Boston, MA
Leerink Partners Global Healthcare Conference
Fireside Chat: Tuesday, March 11 at 9:20am ET
Location: Miami, FL
Barclays 27th Annual Global Healthcare Conference
Fireside Chat: Wednesday, March 12 at 3:30pm ET
Location: Miami, FL
UBS Virtual CNS Day
Fireside Chat: Monday, March 17 at 10:00am ET
Location: Virtual
RBC Inaugural Virtual Ophthalmology Conference
Fireside Chat: April 3 at 8:15am ET
Location: Virtual
Live webcasts of select fireside chats can be accessed in the Investors section of REGENXBIO's website at www.regenxbio.com. An archived replay of the webcast will be available for approximately 30 days following the presentation.
ABOUT REGENXBIO Inc.
REGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. Since its founding in 2009, REGENXBIO has pioneered the development of AAV Therapeutics, an innovative class of gene therapy medicines. REGENXBIO is advancing a pipeline of AAV Therapeutics for rare and retinal diseases, including RGX-202 for the treatment of Duchenne, ABBV-RGX-314 for the treatment of wet AMD and diabetic retinopathy, being developed in collaboration with AbbVie, and RGX-121 for the treatment of MPS II. Thousands of patients have been treated with REGENXBIO's AAV Therapeutic platform, including Novartis' Zolgensma® for children with spinal muscular atrophy. Designed to be one-time treatments, AAV Therapeutics have the potential to change the way healthcare is delivered for millions of people. For more information, please visit WWW.REGENXBIO.COM.
Contacts:
Dana Cormack
Corporate Communications
This email address is being protected from spambots. You need JavaScript enabled to view it.
Investors:
George E. MacDougall
Investor Relations
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$5.94 |
| Daily Change: | -0.22 -3.57 |
| Daily Volume: | 624,507 |
| Market Cap: | US$294.330M |
March 19, 2025 March 13, 2025 March 10, 2025 March 04, 2025 January 30, 2025 | |
ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MORE
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MORE
